FDA approves Moderna mRNA flu vaccine for adults 65+

The U.S. Food and Drug Administration on Friday approved the first mRNA-based vaccine for influenza, a landmark decision that expands the use of the technology beyond COVID-19 but does not mean the government is fully embracing it for all diseases. The vaccine, developed by Moderna, targets both influenza and COVID-19 and is intended for adults aged 65 and older. The approval signals a cautious step forward for mRNA technology, which uses genetic instructions to prompt cells to make proteins that trigger immune responses.

The move comes after years of research and the rapid deployment of mRNA vaccines during the COVID-19 pandemic. Before 2020, mRNA vaccines were largely experimental, with no approved products on the market. The pandemic forced a global sprint to develop and test the technology at scale, proving its speed and adaptability. Now, researchers and companies are exploring whether mRNA can be used for other infectious diseases like flu, RSV, and even malaria. The flu vaccine approval is a test case for how regulators and the public will accept mRNA for other uses.

The FDA’s decision was based on clinical trial data showing the vaccine’s safety and effectiveness in preventing flu in older adults. Moderna’s vaccine, called mRNA-1010, demonstrated a strong immune response and met key endpoints in trials. Still, experts caution that this does not mean mRNA vaccines will replace traditional flu shots anytime soon. Traditional flu vaccines, which use weakened or inactivated viruses, have decades of safety data and widespread public trust. The new mRNA flu vaccine may offer slightly better protection, but it will compete in a crowded market dominated by long-established options.

What happens next could shape the future of mRNA vaccines in the U.S. If the vaccine gains widespread use, it could pave the way for more mRNA-based shots for other diseases. But if uptake is low or side effects emerge, it could slow the technology’s expansion. The CDC still needs to recommend the vaccine before it can be widely used, and insurers will decide whether to cover it. For now, the approval is a cautious vote of confidence—but not a full-throated endorsement—of mRNA’s role in public health.